Company Profile

Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics

 

 

Supervisory Board

 

Chalom Sayada, M.D., Ph.D. - President

Co-founder and CEO of Advanced Biological Laboratories SA, Chalom Sayada previously served as CEO of Sequoia Pharmaceuticals Inc (2004), President and CEO of ActivBiotics Inc. (2000-2003), Vice President at Visible Genetics (1998-2000), President and CEO of ACT Gene SA (1996-1998) which was acquired by Visible Genetics Inc (NASDAQ) in 1998, and Product and Scientific Manager for Roche Diagnostics (1993-1996).

Chalom has extensive experience gained from his positions in early and clinical development at pharmaceutical and diagnostics companies in the United States and Europe. He has helped raise more than $50 million in venture capital financing, completed international in- and out-licensing agreements and has a broad experience in infectious diseases, oncology and human genetic diseases.

 

Elisabeth Ourliac, LLB(Hons), MBA - Vice-President

Elisabeth Ourliac is Vice President Strategy at Airbus , the leading aircraft manufacturer. Prior to this role, Elisabeth was Head of Audit and Risk for Airbus , responsible towards the audit committee of the Board (British Aerospace and EADS shareholders). Elisabeth began her professional career in an Audit firm and joined shortly after Aerospatiale, the French aerospace company which cofounded Airbus . She held various senior executive positions -eg Controller for the commercial aircraft division- in which she directly contributed to the restructuring of the European Aeronautical Industry with the merge of Aerospatiale/Matra and the creation of EADS She then closely contributed to the integration of the Airbus Company between the industrial players of the 4 nations (France, Germany, UK and Spain).
Elisabeth speaks three languages ( French, English and German ). She holds a Master of Business Administration from the Toulouse Business School, majoring in Finance. Additionally she holds a Bachelor in law from the University of Toulouse.
She is the chairman of the board of IAE (School of management of the University of Toulouse), Administrator of the Toulouse Business School foundation and plays an active role in connecting the higher education institutions with the business world and its industrial actors.
Elisabeth is a Member of the “Centre d’Etudes et de Prospective Strategique “ and co-chairs the Toulouse chapter.
She is also a Member of IAWA (international Aviation Women Association) and of ” Institut Français des Administrateurs “.
Elisabeth was awarded Chevalier de la Légion d’Honneur in 2010. 

 

Neil Butler - Member

Chairman of Atlas Genetics (2011- Present), Director of Radisens Diagnostics (2011- Present) and Founding Chief Executiveof Spectromics (2014- Present). He was the founding CEO of Vivacta in 2004 which was acquired by Novartis in 2010. In 1999 on returning from the US he wasfounding CEO of Oxford Biosensors (1999-2004).
For the past 15 years he has managed businessesfocused on developing novel technologies for in vitro diagnostic applications.He has worked both in the US and Europe in senior management positions forbusinesses that develop and manufacture medical products meeting globalregulatory requirements.
He graduated from Portsmouth, UK in Engineeringin 1976.

 

Nicolas Conti, Ph.D. - Member

Nicholas Conti joined Quest Diagnostics in 2006 as the Deputy Chairman in charge of licensing agreements, technological partnerships and the development and management of strategic alliances. He has been involved in a large number of mergers and acquisitions.

Nicholas has over 16 years of experience in the medical equipment and diagnostics sector. He was Deputy Chairman of Business Development at Becton Dikson, where he managed projects dealing with licensing agreements, strategic planning and the creation of new engines of growth.

He began his career, and spent 10 years, with Union Carbide as a researcher in their plastics division. He went on to become the division's coordinator for catalysis research before obtaining his MBA from the Wharton Business School. He subsequently joined the central division in the licensing agreements, mergers and acquisitions, and dispositions sectors. His team was in charge of a $100M budget for licensing agreements worldwide. Nicholas Conti completed a chemistry degree at the University of Notre Dame and a doctorate in chemistry at the University of Florida. He also holds an MBA from the University of Pennsylvania's Wharton Business School.

 

Stéphane Verdood, M.Sc., MBA - Member

Currently a Partner at Vesalius Biocapital, Stéphane Verdood has 25 years’ experience as a Business Consultant in the healthcare, pharmaceutical and biotechnology industries. He co-founded Value for Growth in 2001 as a venture coach for mainly young biotechnology companies and has assisted more than 10 start-up companies in fundraising. Stéphane worked for more than 15 years at Arthur Andersen as a business consultant to the pharmaceutical industry. He successfully merged and reorganized hospitals in Europe and re-structured European pharmaceutical companies in the areas of R&D, distribution and sales. In 1995 he founded Andersen Business Consulting in Belgium.

Stéphane holds a M.Sc. in commercial engineering as well as a MBA from the University of Leuven.

 

Tamar Saraga - Member

Currently as International Executive Advisor in Mergers & Acquisitions and Strategy, Tamar Saraga is helping Corporations and Startups to improve their operations and grow their business in cross-border Mergers & Acquisitions, Strategy, Scouting and EMEA Business Development. She is also an advisor and mentor in several Startups Accelerators. 

With a proven experience of 25 years in the High Technology Industry in international executive positions, she is a former executive of Oracle Corporation where she spent 15 years (1996-2011), lately as Europe, Middle East and Africa M&A and Strategy Senior Director and previously as Chief Operating Officer (COO) of ORACLE France. Tamar has led dozens of local and cross-borders M&A projects to success since 2004 and has managed the multi years Strategic Plan for Oracle EMEA from the definition phase up to the follow up of its execution across 60 countries and among the 22000 employees of the organization  generating 11.5B$ revenue per year.
Tamar is graduated from the Technion, Israel Institute of Technology with a B.Sc degree in Computer Sciences and Information Systems.

 

Isabelle Racamier, MIM - Member

Isabelle Racamier is the Managing Director of Arlys Consulting, a management consultancy advising innovative and growth-oriented companies in the Life Sciences field. Isabelle Racamier has 25 years of experience in the pharmaceutical and biotechnology industries, in controlling, strategic planning, marketing and general management. Isabelle Racamier has held increasingly responsible positions in France, Switzerland, the USA, Japan and Austria with Novartis, Boehringer Mannheim (now part of Roche) and Sanofi. She was the General Manager of Sanofi in Austria from 1998 to 2005, consistently generating yearly double-digit growth during this time. Isabelle Racamier served as a Board member of the Franco-Austrian Chamber of Commerce from 2002 to 2009.

Isabelle Racamier earned her Master’s in Management from ESCP-Europe in Paris. She received executive training in Marketing at INSEAD.

"I am pleased to join Genomic Vision’s Supervisory Board at this important moment when the company is extending its market presence with its unique genetic testing technology and a clear vision for meeting major unmet medical and research needs."

frise

 

genomic_web_visuels_footer_COMPANY